The cholinergic system exerts opposing effects on memory at different stages of disease progression in Alzheimer's and Down syndrome model systems
Alzheimer's & Dementia · 2026
DOI: 10.1002/alz.71154 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2026. Verfasst von Christos Panagiotis Lisgaras und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, New York University Grossman School of Medicine, New York, New York, USA. Hauptthemen laut MEDLINE: Down Syndrome, Alzheimer Disease, Memory, Memory Disorders. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 109 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIA NIH HHS, CURE Epilepsy Award, New York State Office of Mental Health.
Themen: Demenz
Abstract (Originalsprache)
INTRODUCTION The long‐standing cholinergic hypothesis posits that cholinergic signaling is uniformly deficient in Alzheimer's disease (AD) and Down syndrome (DS). We tested the hypothesis that this deficiency occurs primarily late in disease, while early stages involve excessive cholinergic signaling, with distinct implications for memory. METHODS Tg2576 (AD model; n = 38), Ts65Dn (DS model; n = 14), and wild‐type (WT; n = 17) mice at young (3 to 4 months) and old (>14 months) ages received treatments to reduce cholinergic signaling (medial septum chemogenetic inhibition, muscarinic antagonist scopolamine) or enhance it (acetylcholinesterase inhibitor donepezil). Memory assessments used novel object recognition. RESULTS Anticholinergic manipulations restored memory in young Tg2576 and Ts65Dn mice but impaired age‐matched WT mice. Conversely, donepezil improved the memory of old Tg2576, Ts65Dn, and WT but not young Tg2576 and Ts65Dn animals. DISCUSSION These findings refine and challenge the cholinergic hypothesis, revealing for the first time a functional shift from cholinergic hyperactivity driving early cognitive impairment to late‐stage degeneration requiring enhancement.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, New York University Grossman School of Medicine, New York, New York, USA.
- The Nathan S. Kline Institute for Psychiatric Research, Center for Dementia Research, New York State Office of Mental Health, Orangeburg, New York, USA.
- Departments of Child & Adolescent Psychiatry, Neuroscience & Physiology, and Psychiatry, and the NYU Neuroscience Institute, New York University Grossman School of Medicine, New York, New York, USA.
ORCID-Profile: Christos Panagiotis Lisgaras, Helen E Scharfman
Förderung
- NIA NIH HHS
- CURE Epilepsy Award
- New York State Office of Mental Health
- National Institute on Aging
Zitieren
APA
Lisgaras, C. P., & Scharfman, H. E. (2026). The cholinergic system exerts opposing effects on memory at different stages of disease progression in Alzheimer's and Down syndrome model systems. Alzheimer's & Dementia. https://doi.org/10.1002/alz.71154
Vancouver
Lisgaras CP, Scharfman HE. The cholinergic system exerts opposing effects on memory at different stages of disease progression in Alzheimer's and Down syndrome model systems. Alzheimer's & Dementia. 2026. doi:10.1002/alz.71154
BibTeX
@article{Lisgaras2026,
author = {Lisgaras, Christos Panagiotis and Scharfman, Helen E},
title = {The cholinergic system exerts opposing effects on memory at different stages of disease progression in Alzheimer's and Down syndrome model systems},
journal = {Alzheimer's & Dementia},
year = {2026},
doi = {10.1002/alz.71154}
}
EUVIMED